For antibody drug conjugates to reach their full potential, developers should focus on addressing current challenges such as safety and efficacy.
Andreas Dreps
Advertisement
Senior VP and Global Head Drug Development Unit, ICON plc
Articles by Andreas Dreps
Advertisement
Latest Updated Articles
Overcoming Challenges in the Development of Antibody Drug ConjugatesPublished: May 7th 2024 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Thermo Fisher, Lundbeck Announce New OpenAI Partnerships Advancing AI in Drug Development
2
ACT Brief: AI Partnerships, Data-Driven Site Activation, and FDA Approval for Omvoh’s Single-Injection Regimen
3
Imfinzi Regimen Demonstrates 22% Survival Benefit in Early Gastric and GEJ Cancer
4
Broad Survival Benefit from MATTERHORN Trial Highlights New Approach to Biomarker Use
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
